deferoxamine has been researched along with Blood Diseases in 23 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 7.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| "Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions." | 5.14 | Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. ( Bachir, D; Bisot-Locard, S; Gardembas-Pain, M; Hacini, M; Merlat-Guitard, A; Pégourié-Bandelier, B; Thuret, I, 2009) |
| "Deferasirox, a tridentate oral chelator approved for the treatment of chronic iron overload due to blood transfusions, offers a promising alternative for patients unwilling or unable to comply with deferoxamine therapy." | 4.84 | Deferasirox. ( Stumpf, JL, 2007) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 3.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| "deferoxamine treatment than combined treatment with deferiprone and deferoxamine." | 2.44 | Light and shadows in the iron chelation treatment of haematological diseases. ( Maggio, A, 2007) |
| " Further experience with DFO is needed, both to identify the optimal dosage and to clarify the risks of long-term therapy in patients with renal failure." | 2.37 | Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine. ( Coburn, JW; Norris, KC, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (56.52) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Porter, JB | 1 |
| Taher, AT | 1 |
| Cappellini, MD | 2 |
| Vichinsky, EP | 1 |
| Thuret, I | 1 |
| Hacini, M | 1 |
| Pégourié-Bandelier, B | 1 |
| Gardembas-Pain, M | 1 |
| Bisot-Locard, S | 1 |
| Merlat-Guitard, A | 1 |
| Bachir, D | 1 |
| Brown, GC | 1 |
| Patton, WN | 1 |
| Tapp, HE | 1 |
| Taylor, DJ | 1 |
| St Pierre, TG | 1 |
| Hoffbrand, AV | 1 |
| Taher, A | 1 |
| SCURO, LA | 1 |
| BROCCIA, G | 1 |
| DOBRILLA, G | 1 |
| TAGLIAMONTE, A | 1 |
| WILKINSON, JF | 1 |
| VENTURA, S | 1 |
| COLI, L | 1 |
| CAHILL, M | 1 |
| RICHMOND, J | 1 |
| Cohen, AR | 1 |
| Stumpf, JL | 1 |
| Maggio, A | 1 |
| Brissot, P | 1 |
| Bourel, M | 1 |
| Simon, M | 1 |
| Jensen, PD | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Ellegaard, J | 1 |
| Borgna-Pignatti, C | 1 |
| Franchini, M | 1 |
| Gandini, G | 1 |
| Vassanelli, A | 1 |
| De Gironcoli, M | 1 |
| Aprili, G | 1 |
| Cartei, G | 1 |
| Barbui, T | 1 |
| Cazzavillan, M | 1 |
| Chisesi, T | 1 |
| Dini, E | 1 |
| Cohen, A | 1 |
| Coburn, JW | 1 |
| Norris, KC | 1 |
| Matsuda, S | 1 |
| Kariyone, S | 1 |
| Dökert, B | 1 |
| Schwenke, R | 1 |
| Neuwirtová, R | 1 |
| Setková, O | 1 |
| Dufek, M | 1 |
| Mainzer, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Platelet Changes in Cases of Iron Overload(IO)[NCT04329377] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506] | 50 participants (Anticipated) | Observational | 2022-07-02 | Not yet recruiting | |||
| Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.[NCT00469560] | Phase 3 | 158 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for deferoxamine and Blood Diseases
| Article | Year |
|---|---|
ADVANCES IN TREATMENT OF DISEASES OF THE BLOOD.
Topics: Anemia; Anemia, Aplastic; Anemia, Pernicious; Bone Marrow Transplantation; Deferoxamine; Drug Therap | 1964 |
New advances in iron chelation therapy.
Topics: Administration, Oral; Deferoxamine; Heart Diseases; Hematologic Diseases; Humans; Iron Chelating Age | 2006 |
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iro | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; | 2007 |
Treatment of transfusional iron overload.
Topics: Administration, Oral; Chelating Agents; Deferoxamine; Erythrocyte Transfusion; Hematologic Diseases; | 1990 |
Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
Topics: Aluminum; Bone Diseases; Deferoxamine; Hematologic Diseases; Humans; Muscular Diseases; Pain; Risk | 1986 |
[Pathogenesis, clinical aspects and therapy of siderophilia (hemochromatosis)].
Topics: Bloodletting; Deferoxamine; Diagnosis, Differential; Diet Therapy; Hematologic Diseases; Hemochromat | 1971 |
1 trial available for deferoxamine and Blood Diseases
| Article | Year |
|---|---|
Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Chelation Therapy; Child; Cross-Sectional Studies | 2009 |
15 other studies available for deferoxamine and Blood Diseases
| Article | Year |
|---|---|
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side | 2008 |
Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
Topics: Adolescent; Adult; Aged; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Erythrocyte | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
[A NEW TEST FOR ASCERTAINMENT OF STATES OF SIDEROSIS: THE DESFERRIOXAMINE TEST. PRELIMINARY RESULTS].
Topics: Anemia; Anemia, Hypochromic; Biomedical Research; Deferoxamine; Hematologic Diseases; Hemochromatosi | 1964 |
[RESEARCH ON DESFERRIOXAMINE B. 3. THE CLINICAL USE OF DESFERRIOXAMINE B].
Topics: Anemia; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Hematologic Diseases; Hemochromatosis; | 1964 |
HAEMOCHROMATOSIS, A BLOOD DYSCRASIA.
Topics: Clinical Laboratory Techniques; Deferoxamine; Diet; Diet, Reducing; Digoxin; Drug Therapy; Hematolog | 1964 |
IRON DEFICIENCY ANAEMIA.
Topics: Anemia; Anemia, Hypochromic; Anemia, Iron-Deficiency; Deferoxamine; Drug Therapy; Hematologic Diseas | 1964 |
[Treatment and prevention of chronic iron overload (author's transl)].
Topics: Bloodletting; Deferoxamine; Hematologic Diseases; Hemochromatosis; Hemosiderosis; Humans; Iron; Live | 1981 |
Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients.
Topics: Adolescent; Adult; Aged; Deferoxamine; Dose-Response Relationship, Drug; Female; Ferritins; Follow-U | 1995 |
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Topics: Adult; Aged; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Hematologic Diseases; Hemato | 1998 |
Desferrioxamine B: reversible side effects of high daily doses.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Ch | 1975 |
Research findings of potential value to the practitioner.
Topics: Bronchitis; Chronic Disease; Deferoxamine; Diagnosis, Differential; Hematologic Diseases; Injections | 1977 |
Significance of iron and iron binding protein in abnormal iron metabolism--iron overload.
Topics: Animals; Deferoxamine; Female; Ferritins; Hematologic Diseases; Hemosiderin; Humans; Iron; Liver; Mo | 1986 |
[The deferoxamine test].
Topics: Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Injections, Intramuscular; Iron; Uremia | 1970 |
[Significance of disorders of hemoglobin synthesis for the clinical practice].
Topics: Anemia, Macrocytic; Anemia, Sickle Cell; Deferoxamine; Erythrocyte Aging; Erythropoiesis; Hematologi | 1967 |